Fact CheckerSign in

NCT07337161Recruiting

Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma

Source: ClinicalTrials.gov · Last updated 13 Jan 2026

Brief summary (registry, in English)

The purpose of this study is to compare the effectiveness and side effects of stereotactic radiotherapy (5 sessions) against conventional (standard) radiotherapy (20-30 sessions) for the treatment of skin cancer involving the head and neck after surgical resection. Stereotactic radiotherapy works in the same way that conventional (standard) radiotherapy does to kill cancer cells by damaging their genetic material and stopping the cancer cells from making copies of themselves. This study will help the study doctors find out if this different approach is the same, better, or worse than the standard of care for your cancer.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
90 (estimated)
First submitted
28 Aug 2025
Start date
Oct 2025
Primary completion date
Sept 2030
Lead sponsor
David Palma
NCT number
NCT07337161

What you commit to

  • Study type: Interventional
  • Planned participants: 90
  • From Oct 2025 to the primary completion date, Sept 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Significant health conditions or contraindications to receiving surgery and radiation
  • History of previous head and neck cancer within 5 years, except for localized skin cancers (i.e. no nodal or distant spread)
  • Prior head and neck radiation involving the ipsilateral parotid or neck. However, prior radiation to the index skin cancer that has led to the parotid nodal disease being treated on this trial is allowed, as long as there is no overlap, or inconsequential overlap, in the judgement of the treating oncologist.
  • Indications for contralateral neck radiation (i.e. contralateral or bilateral lymph nodes)

Other illness

  • Definite metastatic disease at diagnosis
  • Previous invasive malignancy within 5 years, unless controlled with no evidence of disease

Other

  • Pregnant or breastfeeding women

Who the study is looking for

  • Age ≥ 18 years
  • Patient able to provide informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Patient is a candidate for curative intent treatment
  • Patient is able to comprehend English adequately to complete patient reported outcome questionnaires
  • Biopsy-confirmed cutaneous SCC
  • Definitive resection of a primary cutaneous tumor within the head and neck
  • Tumor stage T1-T4 (AJCC 8th edition); or tumor stage unknown (T0/Tx) with a positive intraparotid, peri-parotid or cervical node that is assumed to be from a head and neck cutaneous SCC by the treating oncologist
  • Nodal stage N1-N3 (AJCC 8th edition)
  • At least 1 indication for adjuvant radiation, including:
    • T3 or T4 tumor stage
    • Lymphovascular invasion (LVI)
    • Perineural invasion (PNI)
    • Positive or close (≤ 3 mm) margin
    • ≥ 1 positive intraparotid, peri-parotid or cervical lymph node
    • Multiple local recurrences or multi-focal disease
  • Neoadjuvant or adjuvant immunotherapy is allowed

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Verspeeten Family Cancer Centre
Coordinator of this site? Confirm its status
LondonCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.